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Introduction 
As C-19 vaccine development is a fast-paced arena, the reader should continue to refer to national 
guidelines and publications which are subject to updates, based on latest research findings. The 
‘Green Book’ – chapter 14a contains up to date guidance on C-19 vaccines, the dose and schedule 
for the UK and recommendations for use of the vaccine (PHE, 2021a).  
Background 
COVID-19 is an infectious respiratory disease caused by novel coronavirus, severe acute respiratory 
syndrome 2 (SARS-CoV-2). Transmission is primarily via respiratory (droplet and aerosol) and contact 
routes. Transmission risk is highest where people are in close proximity of one another (within 2 
meters). Airborne transmission may also occur in health and care settings where aerosol generating 
procedures are performed (PHE, 2020a).  
Specific pre-existing comorbidities present an increased risk of severe infection and hospitalization, 
including dementia, type 2 diabetes, COPD and pneumonia (Atkins et al 2020); increasing age and 
male gender also places individuals at higher risk of morbidity and mortality (Xiaochen et al 2020).  
Emerging data suggests BAME individuals are at increased risk of infection with increased incidence 
of morbidity, ITU admission and mortality in comparison to white individuals (Pan et al 2020). 
In the UK, the likelihood of a front-line health care worker reporting a positive C-19 test is increased 
in comparison with the general community alongside associated factors of supply of PPE, clinical 
setting and ethnic background (Nguyen et al 2020).  
The high number of cases and related morbidity and mortality have laid bare the far-reaching impact 
of pandemic infection across the globe. As of mid-February 2021, there have been over 100 million 
confirmed cases globally, including over 2.3 million deaths (representing a global mortality of 2.2%). 
Europe and the Americas have been particularly affected and within the UK the current incidence of 
confirmed cases is almost 4 million with over 115,000 associated deaths, representing UK based 
mortality of 2.9% (WHO, 2021a).  
The far-reaching impact of C-19 has demanded the development of safe and effective prophylactic 
vaccines, resulting in novel techniques for vaccine development, global collaboration and large 
cohort clinical trials, at a scale and pace not seen before. These developments will change the face of 
approaches to vaccination for years to come and will serve to contain the pandemic and limit the 
associated health, economic and social consequences of the disease.  
In the UK, 3 vaccines have been authorised for supply; two use an mRNA platform (Pfizer BioNTech 
COVID-19 mRNA Vaccine BNT162b2 and Moderna mRNA-1273 COVID-19 vaccine) and the third uses 
an adenovirus vector (AstraZeneca COVID-19 vaccine) (PHE, 2021a).  
mRNA vaccines 
The potential of mRNA vaccines has been acknowledged for some time, with the first invitro success 
in the 1990’s; mRNA vaccines present a number of advantages over subunit, live attenuated, killed 
and DNA-based vaccines. There is no risk of infection or mutagenesis; mRNA is degraded by normal 
cellular processes; its half-life and immunogenicity can be regulated, which in turn increases the 
safety profile. Furthermore, the use of carrier molecules in contrast to the use of a viral vector, 
means anti-vector immunity is avoided, meaning the vaccine can be administered repeatedly. 
Importantly, mRNA vaccines have the potential for fast, scalable production and modification (Pardi, 
2018), essential in response to new virus variants.   
Pfizer BioNTech - BNT162b2 and Moderna mRNA-1273 COVID-19 vaccines 
Approved for emergency use in the UK in December 2020 and January 2021 respectively, the Pfizer 
BNT162b2 and Moderna mRNA-1273 COVID-19 vaccine candidates are lipid nanoparticle-
formulated, nucleoside-modified RNA vaccine that encode for a full-length SARS-CoV2 spike protein 
(Polack et al, 2020; Baden et al 2021). Essentially, a piece of genetic code, isolated from the 
sequenced DNA of the virus, is encased within a fat molecule which instructs the cell to make the 
spike protein displayed on the surface of COVID-19 cells (antigen), thus initiating an immune 
response resulting in antibody production and mobilisation of T cells, conferring protection against 
further exposure to SARs-CoV2.   
A summary of the mode of action of mRNA vaccines is provided in figure 1.   




Adenoviral vector vaccines 
Adenoviruses are a group of common and diverse DNA viruses which cause non-life-threatening 
infection in a diverse range of hosts (Singh et al 2020). Adenovirus vectors have been developed to 
be used as gene delivery systems, or ‘platforms’ for recombinant DNA vaccines; vector-based 
vaccines can be produced at relatively low cost in a short space of time (Sayedahmed et al, 2020). 
Some studies have highlighted draw backs to the use of this vaccine technology with focus on pre-
existing or the development of immunity, meaning a range of viral vector candidates may be 
required over time as more individuals are exposed to the adenoviral vector-based vaccine (Singh, 
2020).  
Astra Zeneca – ChAdOx1 nCoV-19 (AZD1222) vaccine 
Approved for emergency use in the UK in December 2020, the ChAdOx1 nCoV-19 vaccine (AZD1222) 
consists of a replication deficient chimpanzee adenovirus vector ChAdOx1, containing SARS-CoV-2 
structural surface glycoprotein antigen (spike protein; nCoV-19) gene (Voysey et al 2021).  
Put simply, this is a chimpanzee adenovirus vaccine vector – a platform to deliver the modified spike 
protein genetic sequence, into the target cells. The is a harmless, weakened virus that usually causes 
the common cold in Chimpanzees.  It has been altered to ensure it cannot replicate in humans 
making it safer for older persons and those with pre-existing conditions. Humans have had minimal 
exposure to it; therefore this vector has been shown to generate a strong immune response 
(University of Oxford, 2020).  
When the adenovirus vaccine enters the cells of the body, it utilises the cell machinery to produce 
the surface spike protein, inducing an immune response as shown in figure 2.  
 




Eligibility for vaccination  
The objective of the vaccination programme is to protect those most at risk of serious illness and 
death (PHE, 2021a). The Joint Committee for Vaccination and Immunisation (JCVI) have set out 
priority groups for those at risk (table 1 and box 1) linked to COVID-19 specific mortality (JCVI, 2020). 
Risk due to increasing age, pre-existing conditions and residence in a care home setting inform the 
priority of vaccination. 
Table 1 - priority groups for vaccination advised by the JCVI  
Priority group  Risk group  
1  Residents in a care home for older adults  
Staff working in care homes for older adults  
2  All those 80 years of age and over  
Frontline health and social care workers  
3  All those 75 years of age and over  
4  All those 70 years of age and over  
Clinically extremely vulnerable individuals (not 
including pregnant women and those under 16 
years of age)  
5  All those 65 years of age and over  
6  Adults aged 16 to 65 years in an at-risk group 
(Table 2)  
7  All those 60 years of age and over  
8  All those 55 years of age and over  
9  All those 50 years of age and over 
 
Box 1: Clinical risk groups 16 years of age and over who should receive C-19 immunisation 
• Chronic respiratory disease  
• Chronic heart disease and vascular disease  
• Chronic kidney disease  
• Chronic liver disease  
• Chronic neurological disease  
• Diabetes mellitus - any type 
• Immunosuppression  
• Asplenia or dysfunction of the spleen  
• Morbid obesity - Body Mass Index ≥40 kg/m². 
• Severe mental illness  
• Adult carers  
• Younger adults in long-stay nursing and residential care settings 
Alongside those at clinical risk, the occupational immunisation programme seeks to protect health 
and social care staff at high risk of exposure who provide care to vulnerable individuals. The 
following occupational groups are prioritised:  
• Staff involved in direct patient care – this includes student nurses 
• Non- clinical staff in secondary or primary care /community healthcare settings 
• Laboratory and pathology staff 
• Frontline social care workers (PHE, 2021a) 
Safety and Efficacy  
It is key that COVID-19 vaccines are safely and effectively delivered to as many of those eligible as 
possible. This will require knowledgeable, confident and competent vaccinators who have 
undertaken the appropriate training and that they are supported and supervised in practice.  To date 
there are a minority of individuals who cannot receive the Pfizer BioNTech, Moderna or AstraZeneca 
COVID-19 vaccines. Vaccinators as part of the consent process, will identify any patients who may be 
at risk and appropriate advice sought.  The vaccine should not be given to those who have had a 
previous systemic allergic reaction (including immediate-onset anaphylaxis) to a previous dose of the 
same COVID-19 vaccine or any component (excipient) of the COVID-19 vaccine e.g., polyethylene 
glycol (Polack et al, 2020a). A very small number of individuals have experienced anaphylaxis when 
vaccinated with the Pfizer BioNTech vaccine. Following close national surveillance, the MHRA is no 
longer advising that individuals with a history of anaphylaxis to any vaccine, medicine or food do not 
get the vaccine. Anyone with a previous history of allergic reactions to the ingredients of the vaccine 




Contraindications, pregnancy, and breastfeeding  
Pregnant women are at higher risk of severe C-19 disease with an associated risk of pre-term birth. 
Clinical trial data is insufficient currently to assess safety and efficacy of C-19 vaccinations in 
pregnant women, or indeed to recommend routine use in pregnancy (PHE, 2021b), however, clinical 
trials are ongoing. Pregnant women should receive vaccination if the benefit outweighs the risk, for 
example, for those women with comorbidities or health care workers (JCVI, 2020; RCOG, 2020). If 
pregnancy is apparent after vaccination, she should complete the pregnancy before finishing the 
recommended vaccine schedule. Routine pregnancy testing or delaying pregnancy prior to 
vaccination is not recommended (JCVI 2020, WHO, 2021b).  
Within the UK, the UK vaccine in pregnancy surveillance programme seeks to compile additional 
information about women who are immunised with specified vaccines whilst pregnant to monitor 
the outcome of such exposures. This data being utilised to gain further information to guide practice 
and provide information. All COVID-19 vaccines given from the first day of last menstrual period to 
any time in pregnancy should be reported to the UK vaccine in pregnancy surveillance programme 
(PHE, 2021b).  
As both Pfizer, Moderna and Astra Zeneca vaccines are non-live, JCVI (2020) advise that 
breastfeeding women may be offered vaccination with either of the approved vaccines within the  
Vaccines are administered by a range of healthcare professionals and other non-registered staff and 
volunteers. To facilitate this the UK government introduced changes to The Human Medicines 
Regulations 2012 to allow an unlicensed medicine to be administered via a Patient Group Direction 
(UK Statutory Instrument 1125, 2020). In cases where vaccines are administered by non-healthcare 
professionals there is a separation between the task of vaccination and the clinical assessment and 
decision making. With the registered healthcare professionals being responsible for the later and the 
non-registered volunteer carrying out the physical task of administering the vaccine. Irrespective of 
whether the vaccinator is a volunteer or a health professional either the NHS Resolution indemnity 
or General Practice / Community Pharmacy third party liability insurance (NHS England, DHSC and 
NHS Resolution, 2020) has provided indemnity to all individuals involved in helping deliver the 
vaccination programme including volunteers.  
 
Training is dependent on the individual employer and the current experience of the practitioner, but 
as a minimum staff are required to have specific training in the storage, dilution (where appropriate) 
and administration of each individual vaccine together with anaphylaxis training. Other statutory 
and mandatory training around information governance, basic life support and safeguarding may 
also be required (Public Health England, 2020a). Health Education England (2021) have developed a 
detailed e-learning package which supports staff with the theory side of training. In addition, 
individual competence assessment tools have been developed to allow for clinical assessment of 
vaccinators (Public Health England, 2020b).  
 
Storage, transit and handling of vaccines. 
At the time of writing the Medicines and Healthcare Regulatory Authority (MHRA) have approved 
three Covid-19 vaccines for use. All three vaccines require two doses.  Each vaccine has its own 
storage and administration requirements. As vaccines are biological products, they are temperature 
sensitive and must be stored and transported within the recommended temperature range (NHS 
England Midlands and East, 2015).  
 
Pfizer BioNTech Vaccine 
The Pfizer BioNTech vaccine is stored at a temperature of minus 70 degrees centigrade and the 
vaccine must be thawed for before administration. There are two permitted ways of thawing the 
vaccine either by allowing vial(s) to thaw in the refrigerator (2°C to 8°C) or by thawing at room 
temperature (up to 25 degrees centigrade) for 2 hours. A carton of vials may take up to 3 hours to 
thaw, and thawed vials can be stored in the refrigerator for up to five days (120 hours). Once thawed 
the vaccine must be used within 5 days (120 hours) and it must be stored in a medical refrigerator at 
a temperature of between 2 and 8 degrees. Once removed from the refrigerator and diluted the 
vaccine must be used within 6 hours (MHRA, 2020a). Care must be taken with the distribution of 
vaccines to clinics and other locations to maintain the vaccine cold chain. The vaccine once thawed 
must be stored in a medical grade refrigerator or if transported (prior to dilution) it should be in a 
medical grade cool bag with minimum and maximum temperature monitoring. Prior to 
administration the Pfizer BioNTech vaccine must be diluted with 1.8 ml of Sterile unpreserved 
Sodium Chloride 9 mg/ml (0.9%) for injection prior to administration – the procedure for the dilution 
of the Pfizer BioNTech vaccine is shown in Box 1.  
[place Box 1 near here] 
Once diluted the vial contains 5 or 6 doses, depending on syringe type used, with each dose being 
0.3 ml. To maximise vaccine from each vial low dead volume syringes should be used. 
 
AstraZeneca Vaccine 
The AstraZeneca vaccine is stored in a medical refrigerator at between 2 and 25 degree centigrade. 
The vaccine comes in two presentations; either a 5 ml (10 dose) multi-dose vial or a 4 ml (8 dose vial) 
– where low dead volume syringes are used it is possible to obtain an additional dose from each vial. 
The dose per patient is 0.5 ml. The vaccine does not require dilution and the vial should be visually 
inspected (the vaccine is a colourless to slightly brown, clear to slightly opaque solution). Care 
should be taken not to shake the vial (MHRA, 2020b).  
 
The ease of storage of the AstraZeneca vaccine makes it ideal for community administration. Care 
must be taken to maintain the vaccine cold chain including transfer of the vaccine to clinic locations 
and to care homes and patient’s homes. Vaccines that are to be used during home visits or 
community vaccination sessions where there are no refrigeration facilities must be transported and 
stored in a medical grade cool box or bag and the box or bag should then be packed following the 
manufacturer's instructions and avoiding overfilling. All vaccines should be kept in their original 
packaging until use and the minimum and maximum temperatures should be recorded whilst 
vaccines are stored in the cool box or bag.  
Once removed from the refrigerator the vial, which contains either 10 or 11 doses or 8 or 9 doses 
depending on size, must be used within 6 hours. Once the vial bung is punctured the date and time 
should be noted on the label to ensure it is used within the time limit.  
 
Moderna Vaccine 
The Moderna vaccine is stored frozen between minus 25 degrees centigrade to minus 15 degrees 
and must be thawed prior to administration. The vaccine can be thawed in a medical refrigerator for 
2.5 hours and then stored between 2 and 8 degrees centigrade for up to 30 days. The vaccine should 
be protected from the light and retained in its original packaging throughout. One removed from the 
refrigerator it can be stored between 8 and 25 degrees centigrade for up to 12 hours. Prior to use 
every vial must be brought to room temperature for 15 minutes. Each vial contains 10 doses of 
vaccine with 0.5 ml being administered to each patient. The vaccine requires no dilution, and the vial 
should be inspected prior to use (the normal appearance being is a white to off-white dispersion. It 
may contain white or translucent product-related particulates). Once punctured the vial should be 
discarded if not used within 6 hours. The date and time should be noted on each vial after the first 
dose is drawn.  
 
Patient Assessment and Consent 
Prior to vaccine administration the patient should be assessed to identify any contra-indications or 
cautions in relation to the vaccine. This includes identifying if the patient has had a previous allergic 
reaction or anaphylaxis, whether they are on anti-coagulants, whether they are pregnant or 
breastfeeding, whether they have had a previous vaccination and whether they are febrile or have 
symptoms of Covid-19.  
If the patient is on anti-coagulants, they need to be advised of the risk of haematoma and the 
vaccinator should take care to apply pressure after vaccination. Previous allergic reactions including 
anaphylaxis may result in a different vaccine being selected or the administration being delayed.   
 
Before giving a COVID-19 vaccine, vaccinators must ensure that they have obtained informed 
consent from the patient or that a best interest decision has been made if the patient does not have 
mental capacity at the time of vaccination. To be able to consent to vaccination, the vaccinee should 
receive an explanation of the treatment and its benefits and risks, ideally verbally from a clinician 
(Department of Health, Scottish Executive, Welsh Assembly and Department of Health Social 
Services and Public Safety, 2006). There is no need to obtain written consent if consent is valid 




All three vaccines are administered via the same intra-muscular route. The vaccine should be drawn 
using a low dead volume syringe (different syringes should be used for different vaccine doses e.g., 
1ml syringe for the Pfizer vaccine to allow 0.3 ml to be accurately drawn. Aseptic technique should 
be observed for vaccination. Once the correct dose is drawn it is administered by injection into the 
deltoid muscle in the upper arm or, if there is insufficient muscle mass in the area of the deltoid or a 
particular reason the deltoid muscle is otherwise unsuitable, into the vastus lateralis muscle in the 
anterolateral aspect of the thigh. Skin cleaning prior to administration is not required and adhesive 
plasters are not usually required post administration. 
 
Following administration, the patient should be given advice about common side effects e.g., sore 
arm, feeling unwell for a day and regarding the need for a second dose which should be 
administered within 12 weeks (Department of Health and Social Care, 2020). If the second dose is 
delayed longer than 12 weeks the second dose should still be given and there is no need to restart 
the vaccination programme (Department of Health and Social Care, 2021). Patients should be 
advised to continue to take precautions around social distancing, hand washing, face coverings etc. 
A vaccination card is usually provided together with a patient information leaflet. Details of clinical 
assessment, consent, and the vaccine (vaccine name, batch number, expiry date, administration site, 
name of vaccinator) is also recorded in the clinical system.  The MHRA have instigated enhanced 
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Box 01: Procedure for the dilution of the Pfizer BioNTech Vaccine 
Step 1 The vials of the Covid-19 Pfizer BioNTech vaccine must be brought up to room temperature 
before dilution and dilution must occur within 2 hours. Clean hands- and put-on gloves. 
Step 2  Before dilution invert vaccine vial gently 10 times. Taking care not to shake the vial. Inspect 
the liquid in the vial (the liquid should be a white to off-white suspension and may contain 
white to off-white opaque amorphous particles). Do not use if liquid is discoloured or if 
other particles are observed. 
Step 3 Obtain sterile 0.9% Sodium Chloride Injection, USP which is supplied with the vaccine. Use 
only this as the diluent. Using aseptic technique, withdraw 1.8 mL of diluent into a transfer 
syringe (21-gauge or narrower needle). Cleanse the vaccine vial stopper with a single-use 
antiseptic swab and allow to dry. Add 1.8 mL of 0.9% Sodium Chloride Injection, USP into the 
vaccine vial. 
Step 4 Equalize vial pressure before removing the needle from the vial by withdrawing 1.8 mL of air 
into the empty diluent syringe. 
Step 5 Gently invert the vial containing the Pfizer-BioNTech COVID-19 Vaccine 10 times to mix it 
taking care not to shake the vial. The inspect the vaccine in the vial (the vaccine should be an 
off-white suspension). Do not use if vaccine is discoloured or contains particulate matter. 
Step 6 Record the date and time of dilution on the Pfizer-BioNTech COVID-19 Vaccine vial label. 
During use store between 2°C to 25°C. Discard any unused vaccine 6 hours after dilution. 
Note following dilution the vaccine should not be transported. 
 
